Core Insights - Health 160 International Limited has been included in the Hang Seng Composite Index, marking a significant milestone since its listing on the Hong Kong Stock Exchange in September 2025 [1][2] - The inclusion is expected to enhance the company's liquidity and valuation as it will attract investment from index funds [1][2] Group 1: Index Inclusion and Market Impact - The inclusion in the Hang Seng Composite Index will take effect after the market closes on March 6, 2026, and will officially start on March 9, 2026 [1] - Health 160's entry into multiple indices, including the Hang Seng Healthcare Index and the Hang Seng Stock Connect indices, is anticipated to broaden its investment appeal to institutional investors [1][2] Group 2: Access to Mainland Investors - Being part of the Hang Seng Composite Index is a crucial prerequisite for inclusion in the Stock Connect program, which allows mainland investors to directly invest in Health 160 [3] - This access to mainland capital is expected to provide a stable influx of funds, improving the company's shareholder structure and stock liquidity [3] Group 3: Business Model and Growth Potential - Health 160 operates a dual-driven business model combining "pharmaceutical health product sales" and "digital healthcare solutions," positioning it as a leader in China's digital healthcare sector [4] - The company has established a vast network, connecting over 44,800 healthcare institutions and 5.69 million registered users, creating a significant competitive barrier [4] Group 4: Financial Outlook and Analyst Ratings - Analysts have expressed optimism regarding Health 160's long-term value, with several brokerage firms initiating coverage and issuing "buy" ratings [5] - Target prices from analysts suggest substantial upside potential, with estimates indicating a nearly 70% increase from current stock prices [5]

Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Health 160 (02656) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Group 1: Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform that connects various participants in the healthcare industry [1] Group 2: Market Impact - The inclusion of Health 160 in the Hang Seng Composite Index may lead to its potential addition to the Stock Connect program, as it meets criteria such as market capitalization, liquidity, and listing duration [1] - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its establishment [1]

招股书显示，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。公司 为客户提供各种医药健康用品，以及全面的数字医疗健康解决方案。此外，该公司亦通过在线医疗健康 服务平台-健康160平台提供数字医疗健康解决方案，赋能整个医疗健康产业链上的各平台参与方。截至 2025年3月31日，健康160的平台自成立以来已累计连接超过44,600家医疗健康机构。 智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果， 其中健康160(02656)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9 日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，健康160有可能 被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

去年12月22日，华芢生物-B(02396)正式挂牌上市。作为一只采用"机制B"发行方案IPO上市的标的，华芢生物首挂当日 表现不佳，报收27.00港元，跌幅达到29.32%。由于自带"港股PDGF第一股"光环，这家公司此前被不少打新投资者视 为年末的"创新药大肉"之一。挂牌首日如此表现显然低于不少投资者预期。 从发行方案来看，华芢生物在发行上采用了"机制B+无基石"方式，倚赖机构投资者作"市场锚定"。如今看来，该方案 对于一家基本面有待提高的未盈利18A而言或许有些激进，但对于当时的华芢生物来说，只是"踩着石头过河"，而这 条路正是健康160踩出来的。 靠"机制B+无基石"博进港股通 2月11日，健康160(02656)股价在低开震荡约1个小时后突然大幅跳水，半个小时内，公司股价从约90港元跳水跌至最 低55港元，盘中股价振幅接近40%，最终公司当日收跌30.73%。公司股价由此回吐年内多数涨幅，总市值一度跌穿 200亿港元。 其实对比华芢生物和健康160的IPO发行方案，投资者不难看出二者间的相似之处。 自去年8月港交所港股发布IPO新规以来，不少企业把公开配售压到10%的下限，"人为制造"极致缩量的流通 ...

2月11日，健康160(02656)股价在低开震荡约1个小时后突然大幅跳水，半个小时内，公司股价从约90港元跳水跌至最 低55港元，盘中股价振幅接近40%，最终公司当日收跌30.73%。公司股价由此回吐年内多数涨幅，总市值一度跌穿 200亿港元。 从发行方案来看，华芢生物在发行上采用了"机制B+无基石"方式，倚赖机构投资者作"市场锚定"。如今看来，该方案 对于一家基本面有待提高的未盈利18A而言或许有些激进，但对于当时的华芢生物来说，只是"踩着石头过河"，而这 条路正是健康160踩出来的。 靠"机制B+无基石"博进港股通 其实对比华芢生物和健康160的IPO发行方案，投资者不难看出二者间的相似之处。 自去年8月港交所港股发布IPO新规以来，不少企业把公开配售压到10%的下限，"人为制造"极致缩量的流通盘，并形 成以机构、基石和锚定投资者为主的发行格局，为公司上市开局"保价护航"。据智通财经APP了解，在选择"机制B"的 基础上，两家公司均选择了"无基石"方案，仅设有"绿鞋"机制。如此一来，其高达90%的国际配售比例在缺乏基石锁 仓情况下，基本只能倚赖机构投资者作"市场锚定"。 根据发行计划，健康160全球发售 ...

2月11日讯，港交所已于2月10日收盘后发布最新认可沽空指定证券名单，健康160(02656.HK)被纳入其 中，受市场短期情绪影响，公司股价出现阶段性波动。实际上此次被纳入沽空名单系港交所基于市场流 动性、市值规模等指标的常规调整，属于港股市场正常交易规则运行范畴，与公司自身基本面、核心业 务运营无任何关联，不会对公司日常经营、战略推进产生实质影响。 据悉，港股市场的沽空机制是成熟资本市场的重要组成部分，旨在提升市场流动性、完善价格发现功 能，港交所会定期对可沽空证券名单进行检讨调整，纳入标准明确且公开——通常包括市值不少于30亿 港元且过去12个月换手率不低于60%的股票，或新上市满足特定市值、成交量要求的股票。健康160此 次被纳入，本质上是其市场流动性、市值规模达到港交所相关标准的体现，并非对公司经营状况、发展 前景的负面评价，更不涉及任何公司层面的风险警示。 从交易数据来看，健康160近期股价整体呈现稳步上行态势，2026开年以来涨幅一度高达62.55%，截至 2月10日，公司收盘价为90.80港元，总市值达305.50亿港元，依旧保持较高的市场估值水平。此次因纳 入沽空名单引发的短期波动，更多是部 ...

Group 1 - The Hang Seng Index rose by 0.43%, gaining 116 points to close at 27,299 points, while the Hang Seng Tech Index increased by 1.10% [1] - Xiaomi Group-W (01810) saw a rise of over 4%, with the new generation SU7 expected to launch in April [1] - The first-day listing of Xian Dao Intelligent (00470) increased by 0.44%, while fishing company Lexin Outdoor (02720) surged by 33% on its second day of trading [1] - The Kintor Group (00148) and Kintor Laminates (01888) experienced gains of 5% and 14% respectively, driven by expected high growth in copper-clad laminate performance by 2025 [1] - The precious metals sector saw gains, with Wan Guo Gold Group (03939) rising over 9% to reach a new high, benefiting from increased gold prices [1] - Tungsten prices continued to rise, with tungsten oxide increasing by 20,000 yuan per ton and ammonium paratungstate rising by 10,000 yuan per ton, leading to a surge of over 12% for Jiaxin International Resources (03858) [1] - China Duty Free Group (01880) rose over 5% following a strong start to the Spring Festival travel season for duty-free shopping in Hainan [1] Group 2 - Gilead Sciences-B (01672) increased by over 6%, with plans to submit an IND for ASC36 oral tablets for obesity treatment to the FDA in the second quarter [2] - Jinli Permanent Magnet (06680) rose over 7% as rare earth prices continue to climb, with institutions predicting a dual increase in valuation and performance for the sector [3] - Mongol Mining (00975) surged over 11% as its BKH gold mine ramped up production and dividend restrictions were gradually lifted [4] - Semiconductor Manufacturing International Corporation (00981) fell by 3.63% post-earnings, with Goldman Sachs indicating that its first-quarter gross margin guidance was below expectations [5] - Health 160 (02656) plummeted by 33%, retracting most of its gains for the year, with its total market value briefly falling below 20 billion HKD [6]

Group 1 - Gold stocks continue to rise, with significant increases in companies such as WanGuo Gold Group (up 9.39%), Zijin Mining (up 3.5%), and Lingbao Gold (up 7.24%), driven by fluctuating gold prices and rising interest rate cut expectations [1][2] - Zijin Mining has approved a three-year production plan for major mineral products from 2026 to 2028, outlining clear production targets [1] - China Duty Free Group reported a 14.71% year-on-year increase in duty-free shopping amounts, totaling 11.585 billion yuan since the policy adjustment [1] Group 2 - Mongol Mining shares rose over 15% during trading, reflecting its transition from a single coking coal producer to a multi-mineral producer, including gold and copper [2] - Semiconductor manufacturer SMIC reported a 12.8% year-on-year increase in Q4 2025 revenue, reaching $2.489 billion, with a 60.7% increase in attributable profit [2] - Health 160 experienced a significant drop of nearly 40%, with its market value falling below 20 billion HKD, indicating a major reversal in its stock performance [2] Group 3 - Xiaomi Group shares increased nearly 5% following a live broadcast by its founder, emphasizing ongoing investments in technology and product development [3] - Zhizhu shares rose over 10% this week, with a cumulative increase exceeding 70%, driven by the launch of a new anonymous model by OpenRouter [3] - Jiantao Group stocks rose due to increased demand for high-end copper-clad laminates driven by AI computing power [3] Group 4 - Jaguar Uranium's stock opened over 35% higher on its debut in the US market but later fell by 23.25%, indicating volatility in its initial trading [4] - NIO shares rose 1.43% as the CEO highlighted significant achievements and future plans for profitability by 2026 [4] - Sohu reported a 6% year-on-year revenue increase in Q4 2025, with a notable reduction in losses compared to the previous year [4] Group 5 - Ferrari's Q4 2025 revenue reached €1.8 billion (approximately $2.14 billion), exceeding expectations, with a positive outlook for 2026 [5] - Philips reported a 1% year-on-year sales increase in Q4, with adjusted EBITA surpassing market expectations, particularly in its personal health segment [5]

公开资料显示，健康160于2025年9月17日挂牌上市。浦银国际此前列出未来12个月限售股解禁市值较高 的部分港股公司，解禁比例高的个股在解禁前后股价或承压。其中，健康160将于9月17日解禁，解禁股 数2.67亿股，占流通股79%。 招股书显示，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。公司 为客户提供各种医药健康用品，以及全面的数字医疗健康解决方案。截至2025年3月31日，健康160的平 台自成立以来已累计连接超过44,600家医疗健康机构，其中包括超过14,400家医院及超过30,200家基层 医疗卫生机构。 健康160(02656)重挫近40%，回吐年内多数涨幅，总市值一度跌穿200亿港元。截至发稿，跌32.1%，报 61.65港元，成交额3283.85万港元。 ...

智通财经APP获悉，健康160(02656)重挫近40%，回吐年内多数涨幅，总市值一度跌穿200亿港元。截至 发稿，跌32.1%，报61.65港元，成交额3283.85万港元。 公开资料显示，健康160于2025年9月17日挂牌上市。浦银国际此前列出未来12个月限售股解禁市值较高 的部分港股公司，解禁比例高的个股在解禁前后股价或承压。其中，健康160将于9月17日解禁，解禁股 数2.67亿股，占流通股79%。 招股书显示，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。公司 为客户提供各种医药健康用品，以及全面的数字医疗健康解决方案。截至2025年3月31日，健康160的平 台自成立以来已累计连接超过44,600家医疗健康机构，其中包括超过14,400家医院及超过30,200家基层 医疗卫生机构。 ...